首页> 美国卫生研究院文献>other >Improved Production Process for Native Outer Membrane Vesicle Vaccine against Neisseria meningitidis
【2h】

Improved Production Process for Native Outer Membrane Vesicle Vaccine against Neisseria meningitidis

机译:改进的针对脑膜炎奈瑟氏菌的天然外膜囊泡疫苗的生产工艺

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An improved detergent-free process has been developed to produce vaccine based on native outer membrane vesicles (NOMV) against Neisseria meningitidis serogroup B. Performance was evaluated with the NonaMen vaccine concept, which provides broad coverage based on nine distinct PorA antigens. Scalable aseptic equipment was implemented, replacing undesirable steps like ultracentrifugation, inactivation with phenol, and the use of preservatives. The resulting process is more consistent and gives a higher yield than published reference processes, enabling NOMV production at commercial scale. Product quality met preliminary specifications for 9 consecutive batches, and an ongoing study confirmed real-time stability up to 12 months after production. As the NOMV had low endotoxic activity and induced high bactericidal titres in mice, they are expected to be safe and effective in humans. The production process is not limited to NonaMen and may be applicable for other N. meningitidis serogroups and other gram-negative pathogens. The current results therefore facilitate the late-stage development and clinical evaluation of NOMV vaccines.
机译:已开发出一种改进的无洗涤剂工艺,以生产基于天然外膜囊泡(NOMV)的抗脑膜炎奈瑟球菌血清群B的疫苗。用NonaMen疫苗概念对性能进行了评估,该概念基于9种不同的PorA抗原提供了广泛的覆盖范围。实施了可扩展的无菌设备,代替了超速离心,用苯酚灭活和使用防腐剂等不良步骤。与公开的参考过程相比,所得到的过程更加一致,并且产量更高,从而能够实现商业规模的NOMV生产。产品质量已连续9批达到初始规格,正在进行的研究证实生产后12个月的实时稳定性。由于NOMV在小鼠中的内毒素活性较低,并具有较高的杀菌滴度,因此有望在人类中安全有效。生产过程不仅限于NonaMen,而且可能适用于其他脑膜炎奈瑟氏菌血清群和其他革兰氏阴性病原体。因此,当前结果有助于NOMV疫苗的后期开发和临床评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号